Keytruda (pembrolizumab)

pCPA File Number: 22165
Negotiation Status:
Concluded with an LOI
Pembrolizumab in combination with chemotherapy, for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumors express PD‐L1 (CPS ≥ 10) as determined by a validated test
Merck Canada Inc.
CADTH Project Number:
pCPA Engagement Letter Issued:
Negotiation Process Concluded: